Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas S Griffith

Showing results (21-30 of 179) with videos related to

Pageof 18
Sort By:
The Journal of Biological Chemistry|July 12, 2003
Structure/function analysis of the murine CD95L promoter reveals the identification of a novel transcriptional repressor and functional CD28 response elementScott A Crist, Thomas S Griffith, Timothy L Ratliff
Seminars in Cancer Biology|February 16, 2013
PMN and anti-tumor immunity--the case of bladder cancer immunotherapyErik L Brincks, Michael C Risk, Thomas S Griffith
American Journal of Obstetrics and Gynecology|December 7, 2007
Cytomegalovirus and the role of interferon in the expression of tumor necrosis factor-related apoptosis-inducing ligand in the placentaJanet I Andrews, Thomas S Griffith, Jeffery L Meier
Experimental Biology and Medicine (Maywood, N.J.)|September 17, 2016
Enteric immunity, the gut microbiome, and sepsis: Rethinking the germ theory of diseaseJavier Cabrera-Perez, Vladimir P Badovinac, Thomas S Griffith
International Reviews of Immunology|November 12, 2002
Cell death and immune privilegeThomas A Ferguson, Douglas R Green, Thomas S Griffith
Apoptosis : an International Journal on Programmed Cell Death|December 30, 2006
Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activityRebecca L VanOosten, James K Earel, Thomas S Griffith
Current Opinion in Investigational Drugs (London, England : 2000)|May 25, 2010
Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancerHenry M Rosevear, Andrew J Lightfoot, Thomas S Griffith
Cancers|November 12, 2013
Advances in Viral Vector-Based TRAIL Gene Therapy for CancerLyse A Norian, Britnie R James, Thomas S Griffith
Immunologic Research|October 6, 2007
Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancerMark P Simons, William M Nauseef, Thomas S Griffith
Journal of Immunology (Baltimore, Md. : 1950)|July 9, 2004
Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulationTroy J Kemp, Jill M Moore, Thomas S Griffith
Pageof 18

Showing results (21-30 of 179) with videos related to

Sort By:
Pageof 18
The Journal of Biological Chemistry|July 12, 2003
Structure/function analysis of the murine CD95L promoter reveals the identification of a novel transcriptional repressor and functional CD28 response elementScott A Crist, Thomas S Griffith, Timothy L Ratliff
Seminars in Cancer Biology|February 16, 2013
PMN and anti-tumor immunity--the case of bladder cancer immunotherapyErik L Brincks, Michael C Risk, Thomas S Griffith
American Journal of Obstetrics and Gynecology|December 7, 2007
Cytomegalovirus and the role of interferon in the expression of tumor necrosis factor-related apoptosis-inducing ligand in the placentaJanet I Andrews, Thomas S Griffith, Jeffery L Meier
Experimental Biology and Medicine (Maywood, N.J.)|September 17, 2016
Enteric immunity, the gut microbiome, and sepsis: Rethinking the germ theory of diseaseJavier Cabrera-Perez, Vladimir P Badovinac, Thomas S Griffith
International Reviews of Immunology|November 12, 2002
Cell death and immune privilegeThomas A Ferguson, Douglas R Green, Thomas S Griffith
Apoptosis : an International Journal on Programmed Cell Death|December 30, 2006
Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activityRebecca L VanOosten, James K Earel, Thomas S Griffith
Current Opinion in Investigational Drugs (London, England : 2000)|May 25, 2010
Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancerHenry M Rosevear, Andrew J Lightfoot, Thomas S Griffith
Cancers|November 12, 2013
Advances in Viral Vector-Based TRAIL Gene Therapy for CancerLyse A Norian, Britnie R James, Thomas S Griffith
Immunologic Research|October 6, 2007
Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancerMark P Simons, William M Nauseef, Thomas S Griffith
Journal of Immunology (Baltimore, Md. : 1950)|July 9, 2004
Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulationTroy J Kemp, Jill M Moore, Thomas S Griffith
Pageof 18